Source: Fortune Business Insights – Biosimilars Market Report
The global biosimilars market is on a robust growth trajectory, driven by rising chronic disease burdens, patent expirations of blockbuster biologics, and the growing demand for cost-effective treatment options. According to Fortune Business Insights, the market was valued at USD 32.97 billion in 2025 and is projected to rise from USD 38.67 billion in 2026 to USD 138.60 billion by 2034, expanding at a CAGR of 17.30% during the forecast period.
Biosimilars are highly similar, clinically evaluated versions of already-approved biological drugs. Unlike generic chemical drugs, biosimilars are not identical copies — they are produced from living cells through complex manufacturing processes. Regulatory bodies such as the U.S. FDA, European Medicines Agency (EMA), and Health Canada have developed stringent approval guidelines to ensure their safety and efficacy before market entry.
Patent expirations of major biologics are a primary growth catalyst. Blockbusters like Humira, Herceptin, Remicade, Stelara, and Avastin have either lost or are approaching patent expiry, opening the door for biosimilar entrants. In September 2023 alone, Johnson & Johnson disclosed the patent expiration of Stelara (ustekinumab), accelerating biosimilar competition.
Cost savings are another critical driver. Biosimilars offer savings ranging from 44% to 69% compared to reference biologics. A RAND Corporation study estimated USD 38.4 billion in projected U.S. savings on biologic expenditure between 2021 and 2025 due to biosimilar adoption.
Regulatory momentum is also accelerating the market. The FDA had approved 43 biosimilars by September 2023, while the EMA has approved 86 since 2006 — primarily in oncology, diabetes, and rheumatoid arthritis.
By Drug Class: Monoclonal antibodies dominate the market owing to widespread use in treating cancer and autoimmune diseases and strong regulatory pipelines. Filgrastim & peg-filgrastim held the second-largest share at 20.9% in 2026.
By Disease Indication: Autoimmune diseases — including arthritis, psoriasis, and Crohn's disease — lead in market share. The cancer segment follows closely, supported by a large and growing pipeline of biosimilar candidates under clinical trials.
By Distribution Channel: Hospital pharmacies hold the largest share, driven by rising awareness and favorable reimbursement policies. Online pharmacies are expected to grow at the highest CAGR through 2034.
Europe dominated the global market with a 50.47% share in 2025, underpinned by EMA's progressive approval framework and payer preference for cost-effective alternatives. North America is poised to grow at the highest CAGR, supported by the FDA's expanding interchangeable biosimilar approvals. Asia Pacific follows as the second-fastest-growing region, with companies like Biocon making strategic out-licensing deals in Japan for biosimilars like ustekinumab and denosumab.
The global biosimilars market is highly competitive, with leading players including:
These players compete through R&D investment, strategic alliances, and multi-country regulatory approvals. Notably, Pfizer's Abrilada received FDA approval as the second interchangeable Humira biosimilar in October 2023, while Boehringer Ingelheim launched Cyltezo — the first interchangeable branded Humira biosimilar — in July 2023.
Q1. What is the size and share of the biosimilars market? According to Fortune Business Insights, the global biosimilars market was valued at USD 32.97 billion in 2025 and is projected to grow from USD 38.67 billion in 2026 to USD 138.60 billion by 2034 at a CAGR of 17.30%. Europe held the dominant regional share at 50.47% in 2025, while monoclonal antibodies led the product segment.
Q2. What is driving the growth of the biosimilars market? Key growth drivers include patent expirations of high-value biologics, rising prevalence of chronic diseases like cancer and autoimmune disorders, increasing regulatory approvals globally, and the significantly lower cost of biosimilars compared to reference biologics — offering savings of up to 69%.
Q3. Which region leads the biosimilars market? Europe leads the global biosimilars market, driven by the EMA's robust approval framework — having approved 86 biosimilars since 2006 — along with strong payer incentives and healthcare cost-reduction strategies. North America is expected to record the highest growth rate through 2034.
Source: Fortune Business Insights – Biosimilars Market Size, Share & Growth Forecast Report, 2034